Eli Lilly Deep Value Research: A Great Company at Too High a Price

Understandability score: 4.5/5. The business model itself is not complex: develop high-value drugs, obtain regulatory approval, build capacity, and sell to patients through global channels while continuously expanding indications. But it is not a "simple business," because profits are ultimately determined jointly by patents, clinical data, reimbursement payment, the supply chain, and life-cycle management. If the stock market closed for 5 years, I would be willing to own this company itself; but I would not be willing to own it at any price.

Industry attractiveness score: 5/5. The reason is not that it "won't fluctuate," but that its underlying demand is extremely deep, high-quality assets are scarce, regulatory barriers are extremely high, and the profit pool is concentrated among the leaders.

Moat Assessment

Fact: the strongest moat is not the brand but patents, clinical data, regulation, and scale. Lilly's core moat comes first from its patent and regulatory barriers. Innovative-drug R&D requires sustained heavy investment supported by clinical success rates; the company invested $13.337 billion in R&D in 2025 and continues to pursue acquired IPR&D and external business development; Foundayo received FDA approval in April 2026, becoming a new oral GLP-1 molecule in weight loss; retatrutide disclosed pivotal Phase 3 obesity trial data in May 2026, with average weight loss of 28.3% at 80 weeks. This shows that Lilly is not coasting on one or two lucky drugs but is continuously extending its platform advantage.

Fact: scale and manufacturing capability have become a second moat. Lilly's fixed-asset purchases were $7.841 billion in 2025, up sharply from $5.058 billion in 2024; the company has stated clearly that it is investing in global facilities to produce current and future products, and that near-term spending will remain significantly elevated. The 10-K also notes directly that drug manufacturing is complex and highly regulated, and that adding or shifting capacity takes "a very long time," large capital expenditure, process adjustments, and regulatory approval. This barrier means that even competitors who hold a molecule may not be able to quickly replicate Lilly's supply chain and delivery capability commercially.

Pricing-power judgment must be restrained. Lilly has a degree of pricing power, but not unlimited pricing power. The evidence is direct: in Q1 2026, Mounjaro and Zepbound revenue continued to surge, but the company simultaneously disclosed that both products faced lower realized prices in the U.S., driven in part by rebate discounts and reduced cash-pay prices. In other words, what Lilly has is "bargaining power driven by clinical value," not a monopoly right to raise prices at will. What matters most to long-term investors is not nominal price increases but the ability to maintain high gross margins and strong cash flow even under net-price pressure. For now this still holds: Lilly's FY2025 gross margin was about 83.0% and its Q1 2026 gross margin about 81.9%.

Item-by-item judgment of other moats. Brand advantage: moderate to strong. For patients and physicians, brand awareness of Mounjaro/Zepbound/Kisunla and others is rising, and LillyDirect has strengthened reach, but the brand itself is not the primary moat. Cost advantage: moderate. Not a cost advantage in the sense of being a low-price manufacturer, but a unit-economics advantage from a high-margin innovative-drug platform layered with scale manufacturing and global distribution. Scale advantage: strong. The combination of revenue, R&D, clinical, manufacturing, and global access is very hard to replicate. Network effects: weak. Pharmaceuticals have no typical internet-style network effects. Switching costs: moderate. Once patients and physicians form habits around efficacy, safety, and administration, there is real migration friction, but the payment system may still drive switching. Channel advantage: moderate to strong. Beyond the traditional wholesale/pharmacy system, LillyDirect provides a supplementary channel. Data advantage: moderate to strong. Large-scale clinical, real-world data, and indication-expansion experience matter, but this kind of advantage ultimately still has to be delivered through products. Corporate culture and operating capability: strong. Sustained high R&D investment, fast ramps, strong execution, and parallel capacity expansion all show strong organizational capability. Capital-allocation capability: good but not yet excellent. The company has a long history of dividends, continuous buybacks, and active reinvestment, and is also doing a great deal of pipeline-type M&A and licensing; the overall direction is reasonable, but continuing large-scale buybacks at a high valuation may not deliver the best returns.

My judgment: the moat is overall "stable to slightly widening." The reason it is widening: the tirzepatide platform has been commercially validated, and Foundayo and retatrutide are deepening the product pipeline; manufacturing expansion will also reinforce the supply moat. The risk of it narrowing comes from payer price pressure, competitor innovation, and a re-rating in which, as obesity drugs move from shortage to improved supply, the market shifts from "who has stock" to "whose profit structure is better." On balance, I give moat strength 4.5/5.

Management and Capital Allocation

Fact: management is broadly trustworthy and fairly well aligned with shareholder interests. Lilly's proxy shows that CEO David Ricks has a stock-ownership requirement of 12 times annual salary, while his actual ownership reaches 412 times; the CFO's requirement is 8 times and other executives' is 6 times. The company prohibits executives from hedging or pledging stock and has a clawback policy; all disclosed NEOs meet the ownership requirement. From a governance-structure standpoint alone, this is far better than many cases of "big companies that talk about long-termism but actually hold very little stock."

Capital-allocation record: right direction, not cheap. The main uses of cash include internal R&D, capacity expansion, dividends, buybacks, debt management, and business development. In 2025 the company generated $16.810 billion in operating cash flow, with $7.841 billion of fixed-asset purchases, $5.384 billion of cash dividends, and $4.108 billion of buybacks; in 2024 and 2023 it also repurchased $2.5 billion and $750 million respectively. The 10-K further shows that as of the end of 2025, the company had $10.9 billion of remaining capacity under the $15 billion buyback program authorized in December 2024. My view is that putting money into R&D and capacity is broadly correct, while putting money into buybacks at high prices can only earn a "neutral" rating. For long-term shareholders, buybacks are not a virtue in themselves; only buybacks when undervalued are genuinely high-quality capital allocation.

M&A and external BD: tilted toward "filling out the platform," not "building scale." Lilly's acquired IPR&D and intangible-asset acquisition spending has been high in recent years: in 2023–2025, acquired IPR&D was $3.80 billion, $3.28 billion, and $2.91 billion respectively; purchases/acquisitions of intangible assets in the cash-flow statement were $3.945 billion, $3.346 billion, and $3.008 billion respectively. By Q1 2026, the company also disclosed signed but not yet completed acquisition agreements with potential closing amounts of up to about $12 billion. My inference is that Lilly is using its financial strength to reinforce the next-generation platform, rather than buying assets indiscriminately to chase nominal revenue scale; but this also means that the quality of capital allocation over the next few years will face stricter scrutiny. As long as these external investments cannot be converted into sustainable ROIC, they will turn from "strategic reinvestment" into an "expensive illusion of growth."

Whether incentives are rational. The three metrics for the 2025 annual cash bonus were product revenue, EPS, and pipeline progress, each weighted 33.3%, with the final bonus paid at 218% of target. Over the long run this scheme is not perfect, because both product revenue and EPS tempt management to focus on near- to medium-term results; but the good side is that it at least includes "pipeline advancement" with equal weight, and mandatory executive ownership plus the hedging ban somewhat mitigate short-termism. I give management and capital allocation 4/5: excellent, but I am not yet willing to rate it "outstanding."

Financial Quality and Owner Earnings

Fact: the financial picture over the past decade is very strong, but cash flow has to be viewed on two levels—"good on paper" and "truly distributable." In 2025 Lilly's revenue was $65.179 billion, up 44.7% from $45.043 billion in 2024; Q1 2026 revenue rose further to $19.799 billion, up 56% year on year, with net profit of $7.396 billion, up 168% year on year. FY2025 gross margin was about 83.0%, operating margin about 40.4%, and net margin about 31.7%; the company's IR disclosed FY2025 ROE of 101.36%, ROA of 21.59%, and ROI of 32.37%, with an FY2025 current ratio of 1.58 and an MRQ current ratio of 1.50. Looking at the income statement alone, this is a near-"dreamlike" high-return business.

But cash flow cannot be judged by a single measure. Using the common "standard free cash flow to equity" approach, which subtracts only fixed-asset capital expenditure, 2025 FCF was roughly $8.969 billion; if you also deduct the "capital expenditure" measure from the IR interactive financial statements—that is, including intangible-asset purchases—2025 FCF was about $5.961 billion. The gap between these two figures is large, and the essence of the gap is not accounting manipulation but the fact that Lilly is doing two things at once: first, massive manufacturing expansion, and second, high-intensity external BD / intangible-asset investment. As a result, LLY's profit is broadly real profit, but "truly distributable cash flow" is significantly lower than the headline profit growth rate, at least over the past two to three years.

Key financial table. The table below is compiled manually from Lilly's IR interactive financial pages and the Q1 2026 10-Q; figures are in billions of dollars unless otherwise noted. FCF(PP&E) = CFO − fixed-asset purchases; FCF(total) = CFO − total capital expenditure on the company's IR basis.

How to read this table. First, both revenue and margins are rising significantly, and not simply by cutting costs but driven by an upgrade in product mix. Second, the share count fell from about 1.101 billion in 2016 to about 945 million in 2025, which helps per-share value over the long run. Third, the real pressure is on the right side of the balance sheet and in working capital: in 2025 accounts receivable rose to $20.155 billion and inventory to $13.744 billion, and in Q1 2026 they rose further to receivables of $18.429 billion and inventory of $14.529 billion; this is consistent with the explosive ramp, channel restocking, and global capacity expansion, but it also means that "growth is not cost-free."

Financial soundness. As of the end of 2025, the company had total debt of $42.503 billion and cash and short-term investments of $7.373 billion; as of March 31, 2026, total debt was $43.4 billion, cash was about $5.282 billion, and there was about $10.1 billion of unused committed bank credit. Based on a rough estimate using FY2025 operating profit and depreciation, net debt/EBITDA remains in a manageable range and interest coverage is very high; the company faces no obvious near-term solvency danger. The real risk is not "whether it will survive" but "whether the capital deployed today can earn a sufficiently high return over the next ten years."

Owner Earnings judgment. Here it is essential to distinguish between fact and estimate. Fact: 2025 net profit was $20.640 billion, depreciation about $2 billion, and operating cash flow $16.810 billion; the change in working capital in 2025 consumed about $8.093 billion of cash, fixed-asset capital expenditure was $7.841 billion, and total capital expenditure was $10.849 billion. Q1 2026 operating cash flow already reached $5.333 billion.

Assumption: the fixed-asset spending of the past two years clearly includes growth spending to prepare for obesity drugs and future oral/injectable products, and cannot mechanically be treated as entirely maintenance spending; but treating external BD entirely as "freely distributable" would be overly optimistic. Inference: after balancing these two points, I prefer to place Lilly's conservative Owner Earnings range at $18-22 billion, with a central estimate of about $20 billion. The logic of this estimate is: starting from FY2025 profit and the Q1 2026 operating trend, acknowledging that 2025 working capital abnormally absorbed cash and that a large part of current PP&E capex is expansion-growth spending, while retaining a discount for maintenance manufacturing investment and recurring BD. View: this shows that Lilly's true earnings power is very strong, but not yet strong enough for me to buy at any price. Using a central estimate of $20 billion in Owner Earnings, the current market capitalization corresponds to about 34-35 times Owner Earnings; for my investment framework, that is still on the expensive side.

Valuation and Margin of Safety

Fact: the market's expectations for Lilly are now very high. The current share price is about $732.03, corresponding to a market capitalization of about $693.8 billion; the company's financial returns in the most recent fiscal year are extremely high, and the market is giving it a large premium for high quality and high growth. The problem is that value investing is not about proving "the company is excellent" but about judging "whether the share price has over-priced that excellence in advance."

Method one: discounting Owner Earnings. The following are my assumptions, not company guidance. The discount rate references the current U.S. 10-year Treasury yield of about 4.57% and the equity risk premium requirement; for conservative investors, I will not use an overly low discount rate. The current U.S. 10-year Treasury yield means that for a stock to clearly beat the risk-free return, it must offer a sufficiently high and sustainable incremental return.

How to interpret it. The inference behind this table is: if Lilly continues over the next decade to be the global leader in the metabolic-disease platform and successfully commercializes follow-on assets such as Foundayo and retatrutide, then the optimistic scenario is not far-fetched; but if you require "a sufficient margin of safety at the time of purchase," you cannot use the optimistic scenario as the basis for buying. For conservative investors, the decision should revolve around the neutral scenario or even the conservative scenario, not around the most beautiful long-term vision. By this framework, the current price is already close to the lower edge of my optimistic range and above the upper edge of the neutral range.

Method two: relative valuation. If you compare LLY with large U.S. drugmakers, the conclusion is clear: it is significantly more expensive. Using current market capitalization and FY2025 data, LLY's price-to-sales ratio is above 10 times, its P/FCF is about 77 times (using the fixed-asset-basis FCF), and a rough EV/EBITDA using year-end debt and cash is in the low-20s; Merck's current market capitalization is about $199.4 billion, with FY2025 sales of $65.011 billion, operating cash flow of $16.472 billion, and capital expenditure of $4.112 billion, giving an equity-market-value-to-FCF multiple that is clearly lower, with a current P/E of about 11.75 times. AbbVie's 2025 sales were $61.160 billion, operating cash flow $19.030 billion, and fixed-asset purchases $1.214 billion, but its GAAP profit and net assets are more affected by acquisition intangibles, fair-value changes, and negative equity, so the PB measure is distorted and should not be compared simply across companies. The conclusion is not that "LLY does not deserve a premium" but that "the market has already given it a huge premium."

Comparison with the strongest competitor. From an operating-quality standpoint, Novo Nordisk is still Lilly's strongest rival. Novo's 2025 sales were DKK 309.064 billion, operating profit DKK 127.658 billion, net profit DKK 102.434 billion, and free cash flow DKK 28.3 billion; at the same time it still holds a 59.6% volume share of the global branded obesity GLP-1 market. This shows that the arena LLY is in is not "winner take all" but a structure of high-barrier duopoly plus other challengers. The implication for valuation is: you should not, just because the company is excellent, ignore the multiple-compression risk that a high valuation brings.

Method three: asset or liquidation value. For Lilly, the asset approach is not friendly and should not be the primary valuation method. At the end of 2025 the company had cash and short-term investments of about $7.373 billion against total debt of $42.503 billion; net cash does not provide a meaningful "floor" for the share price. At the same time, the PP&E, intangible assets, and goodwill on the books obviously have value, but a drugmaker's truly most valuable assets are its products still within their patent life, clinical data, manufacturing know-how, future indications, and pipeline optionality—none of which would be decently reflected in liquidation value. My view is that Lilly is not a "cheap-asset stock" but a "great-business stock"; that being so, you need to be all the more conservative on the purchase price.

My valuation conclusion. Conservative intrinsic-value range: $330-420. Fair intrinsic-value range: $560-680. Optimistic intrinsic-value range: $820-980. At the current price of about $732, the market is roughly pricing in "a high-quality company + neutral-to-optimistic medium-to-long-term delivery." Therefore: Ideal buy-price range: $450-575; Acceptable holding-price range: $575-750; Price range I consider clearly overvalued: above $850. This is not precise science but a range judgment based on conservative Owner Earnings and a return requirement.

Margin-of-safety judgment: insufficient. The most fragile assumption in the valuation is the market's default that Lilly will not only hold its tirzepatide lead but also smoothly commercialize the next-generation oral and triple-agonist platforms while maintaining extremely high margins under net-price pressure. If growth comes in below expectations, margins retreat, or the valuation multiple contracts toward the more normal range of high-quality large caps, then even if the company is still a good company, the investment return could be markedly below expectations. For long-term owners, this is exactly the classic risk of "good company but bad price."

Risks, Comparisons, Checklist, and Final Judgment

The most important risks. First, competitive risk: Novo Nordisk is still strong, and other companies are catching up in the metabolic arena; if the clinical gap narrows, price and channel competition will become more brutal. Second, regulatory and payment risk: Lilly itself has flagged that obesity-drug reimbursement coverage, voluntary price agreements, and international reference pricing could all compress net price; in Q1 2026, Mounjaro/Zepbound already showed lower realized prices. Third, capacity and supply-chain risk: the company has expanded capacity aggressively in recent years, and if demand forecasts are wrong, massive capital expenditure could turn into low-return assets; conversely, if supply cannot keep up, it would bring shortages and reputational loss. Fourth, product-concentration risk: in Q1 2026 the metabolic business made up nearly 80% of revenue, and Mounjaro + Zepbound have become the core economic engine. Fifth, legal and accounting risk: the company has disclosed product-liability litigation related to incretin drugs; in addition, large acquired IPR&D, intangible-asset transactions, and working-capital swings make the gap between GAAP and the various "free cash flow" measures large, and investors who look only at EPS can easily be misled.

The strongest counterargument. The most powerful counterargument is not "Lilly is not a good company" but "when you buy today, you have already paid for many years of flawless execution to come." What the bears really see may be three things: first, after tirzepatide's enormous success, the market will naturally extrapolate the short-term ultra-high growth for too long; second, obesity drugs may ultimately evolve into a huge but persistently net-price-pressured chronic-disease category; third, the current profit peak partly benefits from product mix, supply-demand mismatch, and the capital market's imagination about platformization, and these factors may not all remain unchanged for ten years. I consider this counterargument valid.

What facts would overturn my judgment. If the following occur over the next two to three years, I would raise my judgment again: first, net-price pressure proves manageable while volume and indication expansion remain strong, proving the company holds both volume and price; second, after expansion is complete, operating cash flow grows significantly faster than revenue and Owner Earnings clearly steps up; third, follow-on assets such as Foundayo and retatrutide deliver at a high rate, showing that Lilly is not merely a company dependent on tirzepatide. Conversely, if the following facts emerge, I would admit I was wrong or at least substantially lower my view: first, growth in tirzepatide-related products comes mainly from cutting prices to win volume, making the high gross margin unsustainable; second, obesity-business reimbursement coverage expands but economic returns deteriorate markedly; third, capacity investment and external BD eat up cash over the long run without delivering higher per-share intrinsic value; fourth, core products suffer a major safety, regulatory, or patent-loss problem.

Comparison with other opportunities. Compared with its strongest competitor, Lilly may be one of the parties with the greatest platform potential in the current metabolic-drug arena; but compared with a broad index, it does not offer a "clearly superior" risk-adjusted return at today's price. SPY is currently about $578.14; the U.S. 10-year Treasury yield is about 4.57%. If you buy LLY, you are actively taking on the extra risks of product concentration, reimbursement payment, R&D delivery, and valuation pullback; therefore, I want it to offer at least a clearly above-index-and-Treasury expected return. At the current price, I do not see a sufficiently clear excess-return advantage. If I could hold only 5 assets, I would put LLY on the candidate list, but I would more likely let it qualify only when it is cheaper.

Investment Checklist.

Open questions and limitations. What this research most needs to supplement further is a like-for-like PB/EV/EBITDA comparison with Novo Nordisk, as well as a more detailed timetable of patent expiry and patent challenges for Lilly's major products; in addition, how Owner Earnings classifies "maintenance capex" and "recurring BD spending" will significantly affect the valuation range. In other words, the biggest technical uncertainty lies not in whether the financials are true but in cash-flow attribution and discounting assumptions.

【Final Rating】 Watch

【One-Sentence Investment Thesis】 Lilly is a scarce, high-quality innovative-drug platform, but the current share price looks more like paying in advance for future success than buying a great business at a conservative price.

【Core Bull Case】

• Tirzepatide has proven itself a top-tier metabolic-disease asset, with Q1 2026 Mounjaro + Zepbound revenue as high as $12.822 billion.

• The R&D platform is deep, Foundayo is already approved, and retatrutide's pivotal Phase 3 data reinforces the next-generation moat.

• 2025 revenue, margins, and ROE/ROA/ROI metrics are all very strong, showing the business model has extremely high economics.

• Massive capacity expansion pressures cash but is also reinforcing the future supply chain and scale barrier.

• Management's ownership requirement is strict and the governance structure is fairly good.

【Core Bear Case】

• The valuation is already high and the margin of safety is not obvious.

• Price and reimbursement-access pressure is already reflected in the financials, and net price may not be able to support the current optimistic expectations over the long run.

• The business is highly dependent on a small number of major metabolic products.

• Capacity expansion, working-capital tie-up, and external BD significantly absorb cash, so Owner Earnings is not as "light" as the headline EPS.

• Litigation, regulation, and competition could all turn a "good company" into a "mediocre-return investment."

【Key Assumptions】

• Tirzepatide can still maintain strong demand and relatively leading clinical value.

• The expansion of obesity-drug reimbursement coverage will not come at the cost of extreme sacrifice of net price.

• After expansion is complete, cash-flow improvement will be faster than capital-expenditure growth.

• At least some of the follow-on assets such as Foundayo and retatrutide can pick up the growth baton.

• Management will not make low-return acquisitions for the sake of scale.

【Fair Buy Price】 I think the more comfortable buy range is $450-575. The basis is that this range is closer to my requirement of buying at a discount to neutral intrinsic value, and it leaves room for a price pullback, slowing growth, or declining margins.

【Target Holding Period】 If you buy, you should view it through the logic of holding a business for more than 10 years, rather than trading on a 12-month target price.

【Expected Annualized Return】

• Conservative scenario: 1%-4%

• Neutral scenario: 6%-9%

• Optimistic scenario: 10%-13% These are rough ranges starting from the current price and based on different growth and valuation-convergence assumptions, not promises.

【Maximum Loss Risk】 If obesity-drug growth slows markedly, net price stays under pressure, and the valuation multiple retreats toward that of a more ordinary large-cap growth stock, then even if the company's business is still fine, a capital drawdown of 30%-45% could occur; if safety/regulatory/litigation events are added on top, the loss could be larger in an extreme case.

【Tracking Metrics】 I suggest continuing to track: net sales of Mounjaro and Zepbound; U.S. and international realized price; the scope of obesity-drug reimbursement coverage; the early ramp pace of Foundayo; retatrutide's subsequent regulatory path; operating cash flow and working-capital changes; when fixed-asset capex declines; total debt and net debt/EBITDA; the capital returns of buybacks and M&A; and major safety and litigation developments.

【Signals That Trigger Re-evaluation】

• Winning volume by cutting prices for several consecutive quarters.

• Operating cash flow significantly lagging profit growth.

• Obesity-drug reimbursement expands but economics deteriorate.

• The next-generation pipeline fails or is delayed.

• Large acquisitions push up leverage without visible high returns.

• Major safety, product-liability, or patent-adverse developments.

【Final Recommendation】 Coolly put, LLY is most likely a business worth respecting over the long run but not necessarily worth owning immediately at a high price. For those who already hold it, I would not lightly dismiss the quality of the business just because it is "expensive"; for those who do not yet hold it and whose risk appetite is balanced and conservative-leaning, I would rather suggest patiently waiting for a better price or clearer cash-flow delivery. True value investing is not about finding the most dazzling company but about acting only when a good-enough company and a good-enough price appear at the same time.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.